GSK/Xenoport’s Sustained-Release Restless Legs Drug Shows Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from a pivotal study presented at the American Academy of Neurology meeting April 17, evaluating GlaxoSmithKline/Xenoport's sustained-release restless legs syndrome drug XP13512, added further evidence to support its safety and efficacy